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Butriptyline Hydrochloride and Imipramine





A comparison between butriptyline hydrochloride and
one of the most widely-used tricyclic antidepressants,
imipramine hydrochloride, was undertaken in 28 patients
suffering from non-psychotic depression in a double-
blind trial. Three criteria-side-effects, depression and
anxiety-were observed at each visit. The scoring system
representing degree of change from one visit to the other
ranged from - 2 to +10, higher values indicating better
reactions to the drug. For each patient, the changes in
individual criteria were accumulated up to the patient's
last visit. The number of patient observations per pair
at weekly or fortnightly intervals varied between 2 and
5. Butriptyline hydrochloride was superior to imipramine
hydrochloride in accumulated change on all three criteria,
the difference being statistically significant at the 99%
level (P<O,Ol).
S. Air. Med. 1., 48, 873 (1974).
Butriptyline hydrochloride is a new antidepressant with
pharmacological properties similar to other tricyclic anti-
depressant drugs, notably imipramine and amitriptyline.
Chemically, butriptyline hydrochloride is dl-lO, ll-dihydro
-N, N, ,B-trimethyl-5H-dibenzo (a,d) cycloheptene-5-pro-
pylamine. Its toxic dose (fD) and its lethal dose (LD50)
in rats and mice are far below those of imipramine.'
The compound is not a mono-amine oxidase inhibitor.
Its pharmacology was investigated by Hen, Stewart and
Voith.' The drug was initially put to clinical trial in
France by Gayral, who concluded that butriptyline hydro-
chloride was a potent antidepressant psychotropic agent,
indicated in mild and intermediate forms of depression
and melancholia and successful in a high percentage of
cases. It was also studied by Grivois' who reported that
butriptyline was easy to manage, and useful for fast
control of anxiety and as an antidepressant for supportive
outpatient psychotherapy.
Other investigators have utilised butriptyline hydro-
chloride for a variety of syndromes, viz. neurotic anxiety
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and reactive depression, anxiolysis and enuresis control
in paediatrics, endogenous depression and involutional
melancholia, and the post-suicide syndrome.' The dosage
utilised by the investigators on their adult patients varied
from 25 to 50 mg of butriptyline hydrochloride 3 - 4
times per day.
The accurate assessment of psychiatric trials is fraught
with difficulty. The terminology used is frequently mis-
leading and often only applicable to separate and specific
schools of psychological thought. The patients themselves
supply the investigator with a subjective impression which
has to be objectively documented into a statistically
meaningful format. If the psychiatric investigator writes
down impressions such as good, worse, mild deterioration,
etc., these subjective descriptive impressions pertain to
his assessment of the patient on that specific day only,
hence uniformity is lost. Many authors have attempted
to grade various aspects and symptoms of depression in
order to subclassify the different variables.
When one has the task of comparing a new psychothera-
peutic drug with another which has been in use for some
time, the situation becomes more complex. One may com-
pare the experimental drug with a placebo on a double-
blind basis from which one concludes that the drug results
are superior to the placebo effect. This comparison serves
as no guideline to the profession. It was considered that the
new preparation should be accurately compared to a stan-
dard one with regard to the effect of each upon measurable
components of anxiety, depression, side-effects, and the
timeous occurrence in the patient, together with severity of
the latter components.
PATIENTS AND METHOD
Many constants had to be standardised before the insti-
gation of the trial:
1. The trial had to be double-blind.
2. The new therapeutic agent and the standard anti-
depressive drug had to be given to matched patient
pairs according to their age, sex and diagnosis.
3. The distribution of both drugs had to be randomised.
4. The diagnoses of the matched pairs had to be
similar according to fixed criteria.
,I
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TAeLIO I. EXAMPLES OF RATING SCALES
Patient Assessment
At every visit, each patient was assessed according to a
rating scale specifically for side-effects, depression and
anxiety. The numeric was encircled by the investigator
on every occasion.




+ 1 Very slow onset of l+ 2 Moderate onset of Mild improvementr 3 Fast onset ofT
+ 4 Gradual }+ 5 Rapid Significant improvement
+ 6 Slow onset of 1
+ 7 Rapid onset of J
Good results
+ 8 Slow onset of 1
+ 9 Rapid onset of f Excellent results
+10 Complete cure
Dosage
To simplify the eXlstmg multiplicity of diagnostic
classifications,"· depressions were considered as falling
into two broad categories, psychotic and non-psychotic.
In this trial, only ambulatory patients with the non-
psychotic depressive syndrome were studied. Non-psychotic
depressions, whether they be part of a cyclic phenomenon
(such as manic depressive illness) or merely consisting of
a single episode, have the following features in common:
1. A pervading feeling of melancholia. The patient may
verbalise this, and appear to be listless and apathetic.
2. A variation in the intensity of the above. The
patient often feels worse in the early hours of the
morning, and this subjective observation eases to-
wards early evening.
3. Marked feelings of unworthiness.
4. 1\ preoccupation with suicide.
5. A disturbance in sleep rhythm. The depressive loses
the second trough of the sleep cycle, wakes in the
early hours and has difficulty falling asleep again.
6. Loss of appetite coupled with weight loss.
7. A preoccupation with hypochondriacal ideas.
8. Diminution of libido.
Only ambulant patients having the above non-psychotic
depressive syndrome were admitted to this trial.
The patients in the trial were matched in terms of sex,
age and diagnosis, their common denominator being the
diagnosis of a non-psychotic depressive reaction with the
above features already described.
Selection of Patients
Sealed containers labelled la or I b were utilised. The
container held either butriptyline hydrochloride 25 mg or
imipramine hydrochloride 25 mg. The same patient re-
ceived the same trial index number throughout the study,
and patients were involved as intimately as possible in
the handling of the trial. The principle of informed consent
was strictly adhered to. They knew that both containers
allocated to them would contain a preparation that would
lift their depression, and the patients were agreeable to
acting in a double-blind trial of this nature. It was agreed
to refer to the preparation merely as the medication, and
not as the pill or the tablet, to preserve the anonymity of
the medication. This was understood by each patient.
There was considerable interest in being actively involved
in a drug study and many patients seemed pleased to
explore as carefully as they could how they felt o"n the
medication. The author had no prior knowledge of the
randomisation of the two therapeutic agents involved in
the trial. Great pains were taken to ensure that neither of
the two agents was visible through the container and that
the author would have no physical contact with the
containers at all.
All interviews began with a simple rating of their state
of well-being and the presence of side-effects. This was
done in an open discussion with the patient, and the final
Severe side-effects
Patient feels very b2d




5. The dosage of both preparations had to be standard
in each case, and variations of dosage were to
progress along similar lines with both drugs.
6. The paired patients had to be seen at equally
distributed intervals by the same investigator.
7. Failure of one of the methods of therapy was
defined as a rapid deterioration over two weeks of
trial time. Cases showing a rapid deterioration before
they had completed two weeks on either .irug had
to be dropped from the trial, and a similarly
matched patient, according to the above patient
selection criteria, recommenced on the same pre-
paration. The :-eason for this was to allow two
weeks on either drug to elapse before any judge-
ment of efficacy could be made.
8. Patients were to be assessed eit!-;er every week or
every fortnight, after the initial consultation, on
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TABLE 11. ACCUMULATED- CHANGES IN SYMPTOMS
On butryptaline hydrochloride On imipramine hydrochloride
Patient No. Side-effects Depression Anxiety Patient No. Side-effects Depression Anxiety
1 28 27 27 1 2 - 2 - 3
2 11 2 2 2 24 7 4
3 33 25 24 3 19 20 17
4 9 6 8 4 0 0 0
5 17 14 16 5 13 1 0
6 33 30 28 6 5 4 2
7 9 5 2 7 4 0 2
8 9 0 0 8 9 0 0
9 27 19 17 9 14 4 1
10 27 19 12 10 16 23 15
11 18 1 1 11 5 6 5
12 27 11 14 12 4 4 1
13 27 19 23 13 27 6 3
14 17 5 3 14 18 8 2
X 20,9 13,1 12,6 11,4 5,1 2,9




TABLE Ill. DIFFERENCES BETWEEN ACCUMULATED
CHANGES IN SYMPTOMS IN EACH MATCHED PAIR
cally significant at the 99% level (P = 0,01), and yields the
estimate that approximately 70% of the patients performed
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STATISTICAL METHOD AND RESULTS
figures circled on the rating scale were seen by the
patient. As soon as the form was completed, it was
sealed and sent to the statistical co-ordinator of the trial.
In this way, each assessment was done without the guide-
line of an earlier rating to set the stage or bias the
results in any way. Ratings were done once a week or
fortnightly.
A measure of the over-all effect of treatment is provided
by the accumulated change in symptoms on each of the
three criteria. These scores were computed for each
subject and are listed in Table 1. A conspicuous feature
of the data is the tendency for high scores on one of
the criteria to be associated with high values on the other
two.
Since the members of each pair were matched, a
suitable measure of the difference in the effect of the
two drugs is obtained by taking the difference in accumu-
lated change between the two members of each pair.
Table IT shows these difIerence.s, the score of the imipra-
mine hydrochloride subject having been subtracted from
that of the butriptyline hydrochloride subject in each case.
Most of the differences are positive, 'suggesting that
butriptyline is superior. To test this hypothesis, the Wil-
coxon matched pairs signed rank test was used. This test
showed that on each criterion butriptyline hydrochloride
was superior to imipramine hydrochloride, the differences
being statistically significant at the 99°~ ievel (P <0,01).
The use of Bonferroni's inequalities shows further that
at a significant level of at least 97~o, butriptyline hydro-
chloride is superior to imipramine hydrochloride on all
three criteria simultaneously. In fact, of the IO pairs in
which one drug performed better than the other on all
three criteria, 9 favoured butriptyline hydrochloride and
one imipramine hydrochloride. This difference is statisti-
J
